Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Pullamsetti, C. Doebele, A. Fischer, R. Savai, B. Kojonazarov, B. Dahal, H. Ghofrani, N. Weissmann, F. Grimminger, A. Bonauer, W. Seeger, A. Zeiher, S. Dimmeler, R. Schermuly (Bad Nauheim, Frankfurt, Giessen, Germany). Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 412

Member's Comments

No comment yet.

Related content which might interest you: Systemic hypoxia contributes to pulmonary hypertension in heart failure Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017 Year: 2018 Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Therapeutic hypercapnia prevents pulmonary hypertension in rats with bleomycin-induced chronic neonatal lung injury Source: Annual Congress 2011 - Resuscitation and ventilation in the baby and infant Year: 2011 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Effects of hypoxia-induced chronic changes in pulmonary haemodynamics on the lung function and responsiveness in rats Source: Annual Congress 2009 - Experimental approaches in animals and modelling in humans Year: 2009 Right lung ischemia induces development of contra-lateral pulmonary vasculopathy Source: Annual Congress 2011 - Pathobiology of experimental pulmonary hypertension Year: 2011 Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 The importance of cardiac function in pulmonary hypertension Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Diaphragm function in experimental pulmonary hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 The progression towards pulmonary arterial hypertension is attenuated by bosentan in scleroderma patients Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease Source: Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019 Year: 2020 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006